Dissecting cause and consequence of the IFN signature in systemic autoimmune diseases

Dissecting cause and consequence of the IFN signature in systemic autoimmune diseases - IFN signature in systemic autoimmune diseases

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON50748

Enrollment

780

Registered

2014-04-30

Start date

2017-11-20

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Antiphopholipidsyndrome primary Sjogren's syndrome Raynaud's phenomenon Rheumatoid Arthritis Systemic Lupus Erythematosus systemic sclerosis

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Age : 18 - 75 years Diagnosed with Raynaud's phenomenon, systemic lupus erythematosus, anti-phospholipid Syndrome, primary Sjogren*s syndrome, systemic sclerosis or rheumatoid arthritis according to current/new ACR/EULAR criteria The non Sjoegren sicca patients (nSS) are characterized by the clinical symptoms of dryness, who do not meet the classification criteria for pSS. Blood from healthy controls is obtained via the "mini-donordienst" and is anonymous, except for age and gender. Additionally, fecal samples from healthy persons, related to the patient, will be collected as a control.

Exclusion criteria

Exclusion criteria: -

Design outcomes

Primary

Measure	Time frame
Novel molecular pathways in biological fluids and cells in patients with systemic diseases in relationship to disease phenotypes.	—

Secondary

Measure	Time frame
Composition of the microbiome (only for patients with Raynaud's phenomenon and SSc)	—

Countries

Netherlands

Outcome results